This immunotherapy was restricted to HLA-A*24:02-individuals (more common in Japan) using peptides derived from five cancer-testis antigens (DEPDC1, MPHOSPH1, URLC10, CDCA1, and KOC1) commonly present in bladder cancer. Here, NUF2 is linked to urinary bladder carcinoma.